Previous studies have demonstrated that RKIP inhibits metastasis in prostate [12-14], breast [15], ovarian [16], colorectal [17, 18], and gastric cancer [19], and melanoma [20], and its expression is predictive of clinical outcome: better outcome with higher expression [12-19]. The gene discussed is PEBP1; the disease is gastric cancer.